Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Addiction Treatment Centers
Transcript
- Lucas: So Luna, I was looking at a deal report from last quarter. Private equity firms poured nearly $3 billion into addiction treatment centers over the past twelve months. That's up from about $500 million five years ago. Luna: Three billion? That's a huge jump. Who's doing the buying? Lucas: Some of the big names you'd expect — Bain Capital, Welsh Carson, a few healthcare-focused funds. But what's interesting is the playbook. It's the classic roll-up: buy small local detox centers and outpatient clinics, then centralize marketing and billing under one roof. Luna: Right, so instead of a dozen mom and pop shops with different websites and phone numbers, you get one regional brand that can negotiate better insurance rates. Lucas: Exactly. And the margins get a lot fatter. One platform called Behavioral Health Partners, backed by a mid-market PE firm, went from 12 centers to 150 in four years. They now cover detox, residential treatment, and outpatient follow-up. It's a funnel. Luna: And what kind of centers are they buying? I mean, addiction treatment ranges from luxury rehabs to Medicaid-funded clinics. Lucas: That's the thing — PE firms are mostly targeting centers that rely on private insurance or out-of-pocket cash. Medicare and Medicaid reimbursements are too low for the math to work. So you're seeing consolidation in the higher-end market, where a 30-day residential stay can run $30,000. Luna: Which obviously raises questions about access. Not everyone can afford that, or has a PPO plan that covers it. Lucas: Absolutely. And there's a lot of debate about how PE ownership affects care quality. A 2025 study in JAMA Psychiatry found that pe backed treatment centers had 20% higher readmission rates within 90 days compared to non pe facilities. But also 30% lower per-patient costs, because they standardized protocols and reduced length of stay. Luna: So you're getting a cheaper stay, but more people coming back. That feels like a trade-off that regulators are starting to notice. Lucas: Yes, and it's drawn scrutiny in states like Florida and Arizona, where the industry has exploded. Florida passed a law last year requiring licensing for all behavioral health marketing services, because some centers were using misleading ads to attract patients. Luna: Misleading how? Lucas: Common tactics: saying they accept all insurances when they actually don't, or promising luxury amenities that turn out to be basic. And there's the broader issue of patient brokering — paying sober homes or halfway houses to refer patients out. It's a gray area that PE firms have sometimes tested. Luna: So you've got this tension: PE brings efficiency and capital to a fragmented industry, but the incentive to fill beds can push against ethical boundaries. How do the firms themselves respond? Lucas: They typically argue that they're professionalizing a space that was often run poorly. They point to standardized clinical protocols, better training for staff, and accountability. And many do produce good outcomes. But the data on readmissions suggests the financial incentives sometimes outweigh the clinical ones. Luna: And that tension between profit motive and mission is something we try to navigate honestly on this show. If that kind of honest analysis has value for you, consider supporting us at buy me a coffee dot com slash fexingo. Lucas: Yeah, listener support is what keeps this show ad-free and independent. It really helps us keep digging into the numbers. Luna: Alright, back to the trend. So aside from the readmission debate, what's the exit strategy? I mean, if you're a PE firm buying up 150 centers, are you eventually selling to a larger platform or taking it public? Lucas: Both have happened. Acadia Healthcare, a publicly traded company, bought several pe backed platforms. There's also been a trend of larger PE funds buying out the mid-market ones. In 2024, we saw a $1.2 billion take-private of a behavioral health chain originally built by smaller funds. Luna: So the consolidation begets more consolidation. Are there any centers that are pushing back, staying independent? Lucas: Some do, especially those with strong brand or reputation in a local market. But as insurance networks tighten and marketing costs rise, it gets harder. You need scale to negotiate rates and to afford the digital ad spend. That's the PE pitch: we can do the back office, you focus on patients. Luna: It sounds almost like the vet clinic or dental office model we've talked about before. Lucas: Very similar. But addiction treatment has higher regulatory risk. You're dealing with federal and state controlled substances laws, HIPAA privacy rules, and a stigma that affects insurance coverage. One bad center can taint the whole network. Luna: I recall a case in 2023 where a pe backed chain in Texas was investigated for overprescribing Suboxone. Did that happen? Lucas: There was a lawsuit, yeah. The chain settled for $15 million. That kind of risk is real. But PE firms argue that a single bad actor doesn't represent the industry, and that better oversight comes from being a large corporate entity. Luna: So what do you see happening next? More regulation, or more growth? Lucas: I think both. We'll see more states follow Florida with marketing and licensing rules. But the demand for treatment is still huge — overdose deaths have plateaued but remain high, and there's a massive unmet need. PE capital will keep flowing, but perhaps into more outpatient and telemedicine models, which have lower regulatory hurdles. Luna: That could be a new angle: virtual addiction treatment. We've seen companies like Boulder Care and Workit Health grow with venture backing, not just PE. Lucas: Exactly. And that's a different conversation. But for the brick and mortar centers, the roll-up wave is still cresting. I've counted at least 30 PE platforms in the space right now, and they're all competing for acquisition targets. The multiples have come down a bit as rates have risen, but it's still an active market. Luna: Interesting. So if you're a small center owner, now might be a decent time to sell, but you need to be careful about who you sell to. Lucas: That's right. The best deals protect the clinical mission while giving the owner liquidity. But not every PE firm is that thoughtful. A good rule is to look at their track record with other healthcare investments — do they have outcomes data? Do they retain clinical leadership? Luna: So it's about finding the right fit, not just the highest offer. Lucas: Exactly. And for the rest of us watching, this space is a litmus test for how private equity handles mission-critical services. We'll keep tracking it. Luna: Thanks, Lucas. That was a lot to unpack. Lucas: Yeah, always is.